Medicis Sues To Block Zydus' Generic Acne Treatment

Law360, New York (June 7, 2012, 5:05 PM EDT) -- Medicis Pharmaceutical Corp. hauled Zydus Pharmaceuticals USA Inc. and its parent company to New Jersey federal court on Tuesday, claiming the drugmakers' proposal to manufacture generic versions of acne drug Solodyn violates three of its patents.

The skin care specialist said New Jersey-based Zydus and Indian parent company Cadila Healthcare Ltd., also known as Zydus Cadila, plan to make generic minocycline hydrochloride extended-release tablets, which infringes U.S. Patent Numbers 5,908,838; 7,790,705; and 7,919,483.

"Medicis will be irreparably harmed if Zydus Cadila and Zydus USA are not...
To view the full article, register now.